
WHAT IS CLAIMED IS

1. A method of preparing a compound of formula (I):




(I)

;

or a pharmaceutically acceptable salt thereof, as a single stereoisomer or enantiomer or a mixture thereof;


wherein the method comprises treating a compound of formula (8):



(8)

;

or a pharmaceutically acceptable salt thereof, with a compound of formula (9):




(9)

;

or a pharmaceutically acceptable salt thereof, under suitable conditions to provide the compound of formula (I), or a pharmaceutically acceptable salt thereof, as a single stereoisomer or enantiomer or a mixture thereof.

2. The method of Claim 1 further comprising a preparation of the compound of formula (8), wherein the method comprises treating a compound of formula (7):




(7)

;

or a pharmaceutically acceptable salt thereof, with a base under suitable conditions to form the compound of formula (8), or a pharmaceutically acceptable salt thereof.


3. The method of Claim 2 further comprising a preparation of the compound of formula (7), wherein the method comprises treating a compound of formula (6):



(6) ;

or a pharmaceutically acceptable salt thereof, under standard Mitsunobu reaction conditions to form the compound of formula (7), or a pharmaceutically acceptable salt thereof.


4. The method of Claim 3 further comprising a preparation of the compound of formula (6), wherein the method comprises treating a compound of formula (5):



(5) ;

or a pharmaceutically acceptable salt thereof, with an aldehyde under suitable conditions to form the compound of formula (6), or a pharmaceutically acceptable salt thereof.

5. The method of Claim 4 further comprising a preparation of the compound of formula (5), wherein the method comprises treating a compound of formula (4):




(4) ;

or a pharmaceutically acceptable salt thereof, under suitable conditions to form the compound of formula (5), or a pharmaceutically acceptable salt thereof.


6. The method of Claim 5 further comprising a preparation of the compound of formula (4), wherein the method comprises:

a) reacting a compound of formula (2):



(2) ;


or a pharmaceutically acceptable salt thereof, with a Grignard reagent of formula (3):



(3) ;

under suitable conditions to form an intermediate product; and


b) reacting the intermediate product of a) with a compound of formula (1):



(1) ;

or a pharmaceutically acceptable salt thereof, under suitable conditions to form the compound of formula (4), or a pharmaceutically acceptable salt thereof.


7. The method of Claim 1 further comprising resolving the compound of formula (I), or a pharmaceutically acceptable salt thereof, under suitable conditions, to yield a compound of formula (I-*S*):



(I-*S*)

;

or a pharmaceutically acceptable salt thereof, and a compound of formula (I-*R*):




(I-*R*)

;

or a pharmaceutically acceptable salt thereof.

8. A method of preparing a compound of formula (II):




(II)

;

or a pharmaceutically acceptable salt thereof, as a single stereoisomer or enantiomer or a mixture thereof;


wherein the method comprises treating a compound of formula (15):



(15)

;


or a pharmaceutically acceptable salt thereof, with a compound of formula (16):



(16) ;

or a pharmaceutically acceptable salt thereof, under suitable conditions to provide the compound of formula (II), or a pharmaceutically acceptable salt thereof, as a single stereoisomer or enantiomer or a mixture thereof.


9. The method of Claim 8 further comprising a preparation of the compound of formula (15), or a pharmaceutically acceptable salt thereof, wherein the method comprises treating a compound of formula (14):



(14) ;

or a pharmaceutically acceptable salt thereof, with an alkylating agent under suitable conditions to form the compound of formula (15), or a pharmaceutically acceptable salt thereof.

10. The method of Claim 9 further comprising a preparation of the compound of formula (14), or a pharmaceutically acceptable salt thereof, wherein the method comprises treating a compound of formula (13):




(13) ;

or a pharmaceutically acceptable salt thereof, under suitable conditions to form the compound of formula (14), or a pharmaceutically acceptable salt thereof.


11. The method of Claim 10 further comprising a preparation of the compound of formula (13), or a pharmaceutically acceptable salt thereof, wherein the method comprises:

a) reacting a compound of formula (12):



(12) ;


with a Grignard reagent of formula (3):



(3) ;

under suitable conditions to form an intermediate product; and


b) reacting the intermediate product of a) with a compound of formula (1):



(1) ;

or a pharmaceutically acceptable salt thereof, under suitable conditions to form the compound of formula (13), or a pharmaceutically acceptable salt thereof.


12. The method of Claim 11 further comprising a preparation of the compound of formula (12), or a pharmaceutically acceptable salt thereof, wherein the method comprises treating a compound of formula (11):



(11) ;

with an oxidizing agent under suitable conditions to form the compound of formula (12), or a pharmaceutically acceptable salt thereof.


13. The method of Claim 12 further comprising a preparation of the compound of formula (11), wherein the method comprises treating a compound of formula (10):



(10) ;


with a suitable alkylating reagent under suitable conditions to form the compound of formula (11).

14. The method of Claim 8 further comprising resolving a compound of formula (II) under suitable conditions to yield a compound of formula (II-*S*):



(II-*S*) ;

or a pharmaceutically acceptable salt thereof; and a compound of formula (II-*R*):




(II-*R*) ;

or a pharmaceutically acceptable salt thereof.

CLAIMS

1. A method of preparing a compound of formula (I):

(I)




or a pharmaceutically acceptable salt thereof, as a single stereoisomer or enantiomer or a mixture thereof;

wherein the method comprises:


a) treating a compound of formula (7):

(7)



or a pharmaceutically acceptable salt thereof, with a base under suitable conditions to form a compound of formula (8):


(8)



or a pharmaceutically acceptable salt thereof; and


b) treating the compound of formula (8):

(8)



or a pharmaceutically acceptable salt thereof, with a compound of formula (9):


(9)



or a pharmaceutically acceptable salt thereof, under suitable conditions to provide the compound of formula (I), or a pharmaceutically acceptable salt thereof, as a single stereoisomer or enantiomer or a mixture thereof.

2. The method of claim 1 further comprising a preparation of the compound of formula (7), wherein the method comprises treating a compound of formula (6):


(6)



or a pharmaceutically acceptable salt thereof, under standard Mitsunobu reaction conditions to form the compound of formula (7), or a pharmaceutically acceptable salt thereof.

3. The method of claim 2 further comprising a preparation of the compound of formula (6), wherein the method comprises treating a compound of formula (5):


(5)



or a pharmaceutically acceptable salt thereof, with an aldehyde under suitable conditions to form the compound of formula (6), or a pharmaceutically acceptable salt thereof.

4. The method of claim 3 further comprising a preparation of the compound of formula (5), wherein the method comprises treating a compound of formula (4):

(4)




or a pharmaceutically acceptable salt thereof, under suitable conditions to form the compound of formula (5), or a pharmaceutically acceptable salt thereof.

5. The method of claim 4 further comprising a preparation of the compound of formula (4), wherein the method comprises:


a) reacting a compound of formula (2):

(2)



or a pharmaceutically acceptable salt thereof, with a Grignard reagent of formula (3):


(3)



under suitable conditions to form an intermediate product; and

b) reacting the intermediate product of a) with a compound of formula (1):


(1)



or a pharmaceutically acceptable salt thereof, under suitable conditions to form the compound of formula (4), or a pharmaceutically acceptable salt thereof.


6. The method of claim 1 further comprising resolving the compound of formula (I), or a pharmaceutically acceptable salt thereof, as a mixture of enantiomers, under suitable conditions; to yield a compound of formula (I-S):

(I-S)



or a pharmaceutically acceptable salt thereof, and a compound of formula (I-R):


(I-R)



or a pharmaceutically acceptable salt thereof.

7. A method of preparing a compound of formula (I):


(I)



or a pharmaceutically acceptable salt thereof, as a single stereoisomer or enantiomer or a mixture thereof, wherein the method comprises:


a) reacting a compound of formula (2):

(2)



or a pharmaceutically acceptable salt thereof, with a Grignard reagent of formula (3):


(3)



under suitable conditions to form an intermediate product; and


b) reacting the intermediate product of a) with a compound of formula (1):

(1)



or a pharmaceutically acceptable salt thereof, under suitable conditions to form a compound of formula (4):


(4)



or a pharmaceutically acceptable salt thereof, as a single stereoisomer or enantiomer or a mixture thereof;

c) treating the compound of formula (4), or a pharmaceutically acceptable salt thereof, as a single stereoisomer or enantiomer or a mixture thereof, under suitable conditions to form a compound of formula (5):


(5)



or a pharmaceutically acceptable salt thereof, as a single stereoisomer or enantiomer or a mixture thereof;

d) treating the compound of formula (5), or a pharmaceutically acceptable salt thereof, as a single stereoisomer or enantiomer or a mixture thereof, with an aldehyde under suitable conditions to form a compound of formula (6):


(6)



or a pharmaceutically acceptable salt thereof, as a single stereoisomer or enantiomer or a mixture thereof;

e) treating the compound of formula (6), or a pharmaceutically acceptable salt thereof, as a single stereoisomer or enantiomer or a mixture thereof, under standard Mitsunobu reaction conditions to form a compound of formula (7):


(7)



or a pharmaceutically acceptable salt thereof, as a single stereoisomer or enantiomer or a mixture thereof;

f) treating the compound of formula (7) or a pharmaceutically acceptable salt thereof, as a single stereoisomer or enantiomer or a mixture thereof, with a base under suitable conditions to form a compound of formula (8):


(8)



or a pharmaceutically acceptable salt thereof, as a single stereoisomer or enantiomer or a mixture thereof;


g) treating the compound of formula (8):

(8)



or a pharmaceutically acceptable salt thereof, as a single stereoisomer or enantiomer or a mixture thereof, with a compound of formula (9):


(9)



or a pharmaceutically acceptable salt thereof, under suitable conditions to provide the compound of formula (I), or a pharmaceutically acceptable salt thereof, as a single stereoisomer or enantiomer or a mixture thereof.


8. The method of claim 7 further comprising resolving the compound of formula (I), or a pharmaceutically acceptable salt thereof, as a mixture of enantiomers, under suitable conditions to yield a compound of formula (I-S):

(I-S)



or a pharmaceutically acceptable salt thereof, and a compound of formula (I-R):

(I-R)



or a pharmaceutically acceptable salt thereof.